摘要
目的分析瑞舒伐他汀对糖尿病并发肾功能不全女性患者介入诊治术后对比剂肾病(CIN)的影响。方法选取2012年12月-2016年10月在医院行介入诊治的2型糖尿病并发肾功能不全的女性患者1 046例,按照治疗方法不同分为试验组536例和对照组510例。试验组患者每晚顿服瑞舒伐他汀10 mg,术前服用≥2 d,服用至介入诊治术后3 d,共≥5 d,对照组患者术前未曾口服瑞舒伐他汀,术后72 h内也禁止口服他汀类药物,72 h后,2组患者均可服用瑞舒伐他汀或其他他汀类药物。比较2组患者临床基线、术后72 h内CIN发生率及1个月内其他终点事件。结果 2组患者临床资料比较差异无统计学意义(P> 0. 05)。2组患者介入诊治相关指标的基线资料比较差异无统计学意义(P> 0. 05)。试验组患者术后发生CIN 11例,发生率为2. 05%;对照组患者发生CIN 27例,发生率为5. 29%,2组比较差异有统计学意义(P=0. 01)。经1个月随访,试验组发生复合终点事件18例,发生率为3. 36%,对照组发生复合终点事件22例,发生率为4. 31%,2组比较差异无统计学意义(P=0. 426),但试验组有减少的趋势。2组均无明显药物不良反应事件。结论瑞舒伐他汀能降低糖尿病并发肾功能不全女性患者介入诊治术后CIN的发生率,对肾功能有保护作用。
Objective To assess the effect of rosuvastatin on contrast-induced nephropathy in women with diabetes complicated with renal insufficiency after interventional therapy. Methods 1 046 female patients with type 2 diabetes complicated with renal insufficiency, who were treated in the hospital from December 2012 to October 2016, were selected. According to different treatment methods, the patients were divided into 536 patients in experimental group and 510＇ patients in control group. Patients in experimental group received rosuvastatin 10 mg every night, 2 days or more before surgery, and 3 doses or more after 3 days of interventional treatment. Control group did not take rosuvastatin orally before surgery. Oral statins were also banned within 72 h, and after 72 h, both groups were able to take rosuvastatin or other statins. The clinical baseline data of the two groups,the incidence of CIN within 72 hours after surgery, and other endpoint events within 1 month were compared. Resuits There was no significant difference in clinical data between two groups （ P 〉 0.05 ）. There was no significant difference in the baseline data of the interventional diagnosis and treatment between two groups （ P 〉 0.05 ）. In experimental group, 11 patients had CIN after operation,the incidence rate was 2.05% ;in control group,27 patients had CIN, the incidence rate was 5.29%, and the difference was statistically significant （ P = 0.01 ）. After 1 month follow-up, 18 cases of composite end point occurred in experimental group, the incidence rate was 3.36% , and 22 cases of composite end point occurred in control group, the incidence rate was 4.31% , the difference was not statistically significant （ P = 0. 426 ）, but the experimental group. There was a decreasing trend. There were no obvious adverse drug reactions in both groups. Conclusion Rosuvastatin can reduce the incidence of postoperative CIN in women with diabetes and renal insufficiency, and has a protective effect on renal function.
作者
朱红昌
邱菊
王士富
张汝敏
王守君
张伟平
ZHU Hongchang;QIU Ju;WANG Shifu(Central Hospital of Zibo,Shandong Province,Zibo 255000,China)
出处
《临床合理用药杂志》
2018年第31期18-20,共3页
Chinese Journal of Clinical Rational Drug Use
关键词
瑞舒伐他汀
对比剂肾病
介入诊疗
Rosuvastatin
Contrast-induced nephropathy
Interventional treatment
